Diffuse Hemispheric Glioma, H3 G34-Mutant Clinical Trials

7 clinical trials for Diffuse Hemispheric Glioma, H3 G34-Mutant across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of 177Lu-PSMA-617 in People With Gliomas — RECRUITING · PHASE1
• Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant — RECRUITING · PHASE2
• 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours — RECRUITING · PHASE1
• Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma — RECRUITING · PHASE1
• 5G-EMERALD: Amivantamab in Malignant Brain Tumours — RECRUITING · PHASE1
• A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma — ACTIVE_NOT_RECRUITING · PHASE1
• Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant — WITHDRAWN · PHASE1

Refine this search